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ABSTRACT
Methyl-5-uridine (m5U) is one the most abundant
non-canonical bases present in cellular RNA, and in
yeast is found at position U54 of tRNAs where mod-
ification is catalysed by the methyltransferase Trm2.
Although the mammalian enzymes that catalyse m5U
formation are yet to be identified via experimental ev-
idence, based on sequence homology to Trm2, two
candidates currently exist, TRMT2A and TRMT2B.
Here we developed a genome-wide single-nucleotide
resolution mapping method, Fluorouracil-Induced-
Catalytic-Crosslinking-Sequencing (FICC-Seq), in or-
der to identify the relevant enzymatic targets. We
demonstrate that TRMT2A is responsible for the ma-
jority of m5U present in human RNA, and that it com-
monly targets U54 of cytosolic tRNAs. By compari-
son to current methods, we show that FICC-Seq is a
particularly robust method for accurate and reliable
detection of relevant enzymatic target sites. Our as-
sociated finding of extensive irreversible TRMT2A-
tRNA crosslinking in vivo following 5-Fluorouracil
exposure is also intriguing, as it suggests a tan-
gible mechanism for a previously suspected RNA-
dependent route of Fluorouracil-mediated cytotoxic-
ity.
INTRODUCTION
High resolution genome- and transcriptome-wide mapping
of RNA modifications has made many advances and re-
ceived considerable attention in the molecular genetics field
in recent years. Despite this, one of the most pressing
questions remains adequate characterization of one of the
more abundant RNA modification types, methyl-5-uridine
(m5U), and in particular, identification of the mammalian
enzyme(s) that catalyse its formation (1). Indeed, any func-
tional characterization of mammalian m5U currently re-
mains extremely limited in the literature, though relevant
efforts would likely be aided via identification of the ge-
netic factors directly responsible for catalysing its forma-
tion. In bacteria and yeast, the enzymes TrmA and Trm2,
respectively, are known to target U54 of tRNAs for methy-
lation (2,3). Based on sequence homology to TrmA and
Trm2, two mammalian m5U-catalysing enzymes are pre-
dicted, TRMT2A and TRMT2B. However, whether these
enzymes represent true m5U methyltransferases, and in-
deed what their respective site-specificities are, remains to
be demonstrated.
Only two of the current high throughput sequencing-
based basic methodological principles used to map RNA
modifications are able to identify sites inherently in anRNA
modification enzyme-specified manner (4). Both initially
described in 2013, these comprise the Aza-IP method used
to identify NSun2- and Dnmt2-dependent human methyl-
5-cytosine (m5C) sites (5), and the methylation-iCLIP
(miCLIP)-based approach previously used to map NSun2-
dependent human m5C (6) and more recently RlmN-
dependent bacterial methyl-2-adenosine (m2A) sites (7).
Such methods are centred on ‘catalytic crosslinking’ prin-
ciples, where the aim is to stabilize and capture catalytic in-
termediates of the in vivo methylation reaction (8). This is
achievable, as during the normal catalytic reaction scheme,
the nucleotide undergoing methylation becomes covalently
crosslinked to the enzyme. In Aza-IP the use of the cytosine
analogue 5-azacytidine is used to stabilize the crosslinked
intermediates, whereas in miCLIP, use of a specific point
mutant form of the enzyme enables crosslink stabilization
(9).
Here we identify TRMT2A target sites in a genome-wide
single-base resolution manner through catalytic crosslink-
ing principles to develop a technique termed ‘Fluorouracil-
Induced-Catalytic-Crosslinking-Sequencing’ (FICC-Seq).
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The method works by incubating cell cultures with 5-
Fluorouracil (5FU); fluorouridine triphosphate (FUTP),
an active metabolite of 5FU, then becomes incorporated
into nascent RNA in competition with uridines during gene
transcription (10,11). Thuswhen anm5Umethyltransferase
proceeds to modify such residues it becomes covalently
crosslinked to them as a normal step of the usual catalytic
reaction (Figure 1A) (12–14). Although FUTP residues
are successfully methylated (15), normal substrate release
does not occur, resulting in a permanent enzyme-RNA cat-
alytic intermediate stabilized via a covalent crosslink oc-
curring on the modified base (Figure 1A) (15–17). Re-
verse transcription of such RNAs will very efficiently stall
at the peptide-RNA crosslink sites, thus enabling reliable
nucleotide-resolution detection of enzymatic target sites
(18). In order to determine the robustness of the FICC-
Seq method, we also performed relevant iCLIP (19) and
miCLIP experiments in parallel. We thereby characterized
TRMT2A as the enzyme commonly responsible for human
cytosolic tRNA-m5U54 formation.
MATERIALS AND METHODS
Cell lines and cell culture
The HEK293 TRMT2A knockout cell line was generated
by GenScript (Hong Kong), and the HAP1 TRMT2A
knockout cell line was purchased from Horizon Discov-
ery; knockout status at protein level was confirmed in our
laboratory using Western blotting. HEK293 cells were cul-
tured in Dulbecco’s Modified Eagles Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS) and
penicillin/streptomycin. HAP1 cells were grown in Iscove’s
Modified Dulbecco’sMedium (IMDM) supplemented with
10% FBS and penicillin/streptomycin. All cultures were
maintained at a temperature of 37◦C in a humidified in-
cubator with 5% CO2. When required, cells were harvested
by washing in phosphate-buffered saline (PBS) and then in-
cubating with Trypsin-ethylenediaminetetraacetic acid fol-
lowed by further washing of detached cells in PBS.
Cellular viability assay
Cell viability was assayed using the RealTime-Glo MT cell
viability assay kit (Promega). Cell monolayers were seeded
at equal densities (∼4000 cells/well) on a 96-well plate and
incubated in 40 l growth media at 37◦C for 24 h. The com-
mercial substrate + enzyme mix and the appropriate 5FU
dose were combined in 40 l media before being applied to
each monolayer (80 l total per well) for a final concentra-
tion of either 0, 10, 100, 1000 or 10000Mof 5FU. After an
initial incubation of 1 h, the first measurement was taken to
establish the baseline and subsequent measurements were
taken over a 48 h incubation period using a Pherastar FS
microplate reader (BMG Labtech).
Western blotting
Western blotting was performed as described previously
(6). Primary antibodies used were mouse monoclonal anti-
TRMT2A (Origene, clone OTI1C3, catalog# TA505555);
mouse monoclonal anti-actin (Santa Cruz); mouse mono-
clonal anti-FLAG (Origene).
Mass spectrometry
Total RNA samples were digested into nucleotides us-
ing 0.6 U nuclease P1 from Penicillium citrinum (Sigma-
Aldrich), 0.2 U snake venom phosphodiesterase from Cro-
talus adamanteus (Worthington), 2 U FastAP (Thermo
Scientific), 10 U benzonase (Sigma-Aldrich), 200 ng Pen-
tostatin (Sigma-Aldrich) and 500 ng Tetrahydrouridine
(Merck-Millipore) in 25 mM ammonium acetate (pH 7.5;
Sigma-Aldrich) over night at 37◦C. The nucleosides were
then spiked with internal standard (13C stable isotope-
labelled nucleosides from Escherichia coli, SIL-IS) and sub-
jected to analysis. Triplicates with 1 g digested RNA and
100 ng internal standard were analysed via LC-MS (Agilent
1260 series and Agilent 6460 Triple Quadrupole mass spec-
trometer equipped with an electrospray ion source (ESI)).
The solvents consisted of 5 mM ammonium acetate buffer
(pH 5.3; solvent A) and LC-MS grade acetonitrile (solvent
B; Honeywell). The elution started with 100% solvent A
with a flow rate of 0.35 ml/min, followed by a linear gra-
dient to 8% solvent B at 10 min and 40% solvent B after 20
min. Initial conditions were regenerated with 100% solvent
A for 10 min. The column used was a Synergi Fusion (4M
particle size, 80 A˚ pore size, 250 × 2.0 mm; Phenomenex).
The UV signal at 254 nm was recorded via a diode array
detector (DAD) to monitor the main nucleosides. ESI pa-
rameters were as follows: gas temperature 350◦C, gas flow
8 l/min, nebulizer pressure 50 psi, sheath gas temperature
350◦C, sheath gas flow 12 l/min, capillary voltage 3000 V.
The MS was operated in the positive ion mode using Agi-
lent MassHunter software in the dynamic MRM (multiple
reaction monitoring) mode. For quantification, a combina-
tion of external and internal calibration was applied as de-
scribed previously (20).
FICC-Seq
Full FICC-Seq methodology is available in the Supple-
mentary Methods. The experiments were performed by im-
muoprecipitating endogenous TRMT2A. Briefly, HEK293
or HAP1 cells were treated with 100 M 5-Fluorouracil
(Sigma) for 24 h and then harvested for the TRMT2A-
FICC-Seq experiments. The cell pellets were disrupted
in lysis buffer consisting of 50 mM Tris–HCL pH 7.4,
100mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulphate,
0.5% sodium deoxycholate and treated with Turbo DNase
(AM2239). Lysates were also treated with a low concentra-
tion of RNaseI (Thermofisher AM2295 at 1:200 dilution) in
order to partially fragment RNAs. Lysates were cleared by
centrifugation at 13 000 r.p.m. for 15min at 4◦C and then
incubated with Protein G Dynabeads (Life Technologies)
in the presence of mouse monoclonal anti-TRMT2A an-
tibody (Origene, clone OTI1C3, catalog# TA505555). Fol-
lowing stringent washing, 3′-end dephosphorylation was
performed with T4 PNK (New England Biolabs) before ad-
dition of a preadenylated linker using RNA ligase (New
England Biolabs). 5′-end labelling was then performed us-
ing T4 PNK and 32P-ATP before protein–RNA complexes
were eluted and run on Bis-Tris polyacrylamide gels. Next,
nitrocellulose transfer was performed and the radioactive
signal was used to dissect nitrocellulose pieces that con-
tained TRMT2A–RNA complexes. RNA was recovered by
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Figure 1. TRMT2A is an m5Umethylase, and 5-Flurorouracil can be used to trap its enzymatic target RNAs. (A) The ‘catalytic crosslinking’ principle for
the m5U modification using 5FU is depicted. During modification of normal uridine residues (top), an m5U methyltransferase (:Enz) becomes covalently
crosslinked to the carbon at position 6 of the base ring. This renders the carbon at position 5 susceptible to electrophilic attack, and amethyl group (supplied
by an S-Adenosyl-Methionine donor, not shown) is transferred to it. Proton abstraction from the 5-carbon occurs next (in an enzyme-dependent manner)
before -elimination of the m5U methyltransferase from the 6-carbon. During modification of 5FU residues (bottom), enzyme-RNA crosslinking and
methyl transfer steps occur normally, but the enzyme cannot mediate fluoride abstraction from the 5-carbon and hence its release from the 6-carbon does
not occur either. (B) Anti-TRMT2A Western of lysates prepared from HEK293 and HAP1 TRMT2A knockout cell lines and control parent cells (top);
anti-actin loading control from the same blot is also shown (bottom). Predicted molecular weight of the native TRMT2A protein is 69 kDa, whilst that of
actin is 42 kDa. (C) Mass spectrometry-based relative quantifications of m5U presence in total RNA from parent (WT) versus TRMT2A knockout (KO)
cells. Experiments were performed in triplicate, and for each LC-MSmeasurement, 1 g of total RNA sample and 100 ng Escherichia coli internal standard
was used. (D) HEK293 cells were treated with 100 M 5FU for 24 h or mock-treated, and immunoprecipitations next performed using anti-TRMT2A
antibody. All samples were treated withDNase, and some samples as indicated were also treated withRNase (RN). RNA components of purified complexes
were radioactively labelled, and complexes then run on a polyacrylamide gel. In samples not treated with RNase, protein–RNA complexes do not efficiently
undergo electrophoresis, and are thus not readily observable. However, in RNase-treated samples, where the RNA component of complexes is digested to a
minimal size, clear bands at just above the predicted molecular weight of TRMT2A are observed following 5FU treatment. (E) FLAG-tagged TRMT2A-
WT (WT) or TRMT2A-catalytic nucleophilemutant (CNM) (see Supplementary Figure S2) were ectopically expressed inHEK293 cells, and an anti-FLAG
antibody was used for the immunoprecipitations. Use of the CNM abolishes the observation of 5FU-induced TRMT2A-RNA crosslinked intermediates
(autoradiograph, left). Control anti-FLAGWestern analysis confirmed that TRMT2A-CNMwas expressed at similar levels to TRMT2A-WT (blot, right).
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz658/5541094 by U
niversity C
ollege London user on 06 August 2019
4 Nucleic Acids Research, 2019
incubating the nitrocellulose pieces in a buffer containing
ProteinaseKand 3.5Murea.Reverse transcriptionwas per-
formed using oligonucleotides containing randomized bar-
codes (UMIs) and two inversely oriented adaptor regions
separated by a BamHI restriction site. cDNAs were size-
purified on TBE-Urea gels before being circularized by Cir-
cLigase II (Epicentre). Circularized cDNAs were then an-
nealed to an oligonucleotide complementary to the BamHI
site and then BamHI digested. Linearized, adapted cDNAs
were then polymerase chain reaction (PCR)-amplified using
Solexa primers with 25 cycles of PCR. Libraries containing
the in-line barcodes were then sequenced on the Illumina
HiSeq4000 platform.
iCLIP
iCLIP was performed as previously described using a UV-
crosslinking based method (19). The experiments were per-
formed by immuoprecipitating endogenous TRMT2A, and
the anti-TRMT2A antibody (Origene, clone OTI1C3, cat-
alog# TA505555) used was the same as that used for
TRMT2A FICC-Seq experiments. Libraries containing in-
line barcodes were sequenced on the Illumina HiSeq4000
platform.
methylation-iCLIP
For methylation-iCLIP experiments, a TRMT2A construct
harbouring the CBM point mutation (Supplementary Fig-
ure S1) and an in-frame FLAG-epitope tag was used. Ex-
ponentially growing cells were transfected with TRMT2A-
CBMusing Lipofectamine2000, and cells were harvested 24
h later. Methylation-iCLIP was subsequently performed as
described previously (6), and using an anti-FLAG antibody
to immunoprecipitate ectopically expressed TRMT2A. Pre-
pared libraries containing in-line barcodes were sequenced
on the Illumina HiSeq4000 platform.
Computational analysis
Although the automated computational pipeline iCount
was originally designed for the analysis and annotation
of UV-induced peptide-RNA crosslinks, we have previ-
ously shown that it is just as informative for character-
izing catalytically induced peptide-RNA crosslinks (6,18).
All sequencing data was processed using the iCount web
server (http://icount.biolab.si) based on the iCount python
package (https://github.com/tomazc/iCount). Briefly, ran-
dom unique molecular identifiers were used to distinguish
and discard PCR duplicate reads, and adaptor/barcode
sequences were then removed (19). Trimmed reads were
mapped to hg19/GRCh37 (ENSEMB v.59 GRCh37) with
bowtie (v.0.12.7) using parameters ‘-v 2 -m 2 -a –best -strata’
(21), and only uniquelymapping reads were used for further
analysis. iCount generated a list of significant crosslinks
based on false discovery rate (FDR) <0.05 by assessing the
enrichment of crosslinked nucleotides at specific sites com-
pared to 100 random permutations (22). A peak calling al-
gorithm was next employed to refine clusters to their most
over-represented crosslink positions (local maxima). For
each cluster the maximal crosslink sites were selected us-
ing a custompython script employing the peakutils package
(https://pythonhosted.org/PeakUtils/index.html) with de-
fault parameters. The maximal cluster positions or ‘peaks’
were then merged across replicates to generate a final clus-
ter list for each experiment. Counts were calculated based
on all overlapping reads for each cluster per replicate us-
ing Bedtools (v2.22). These counts were normalized and
processed using the DESeq2 package which included pre-
filtering of low count clusters, estimation of size factors, and
dispersion for library normalization. Size factors are ob-
tained based on the ratios of total reads per sample whilst
dispersions are estimated using expected mean values from
the maximum likelihood estimate of log2 fold changes. Fi-
nally a generalized linear model is applied using a nega-
tive binomial distribution to identify significant changes in
cluster counts between conditions. For the detection of en-
riched motifs associated with target bases, sequences flank-
ing the crosslink sites (50 bp upstream and downstream)
were extracted using BEDtools v.2.27.0 and run inMEME-
ChIP formotif discovery and search.MEME-ChIPwas run
with reverse complement scans disabled and centrimo in
local mode. Sequences matching the top discovered motif
generated (E-value < 0.05) were further filtered to retain
the matches with the most common position (±1) contain-
ing the crosslink site. Final cropped alignments were con-
verted to motifs using the R packages ggplot and qqseq-
plot. Peak position count correlations (Pearson) within and
between experiments were obtained using R and plotted
with PerformanceAnalytics (https://github.com/braverock/
PerformanceAnalytics) or the R package corrplot. Com-
parisons of peak position distribution across experiments
were conducted and plotted using InteractiVenn and the R
package eulerr. The tRNA structural consensus was built
from the tRNAscan-SE v.2.0 results available at GtRNAdb,
with nucleotide counts binned relative to the structural
region they belonged to (23). Introns were removed and
defining regions (loops and stems) identified using custom
scripts. The final consensus region lengths and sequence
were determined by average and max frequency.
RESULTS
TRMT2A is the major human m5U RNA methyltransferase,
and is amenable to catalytic crosslinking-type experiments
Mammalian TRMT2A displays only modest sequence ho-
mology to the established yeast m5U methyltransferase
Trm2. In order to determine whether human TRMT2A
does indeed truly represent a cellular m5U methylase,
we utilized two independent CRISPR-Cas9 mediated
TRMT2A knockout cell lines (Figure 1B) for relevant mass
spectrometry analysis. Strikingly, in both the HAP1 and
HEK293 TRMT2A knockout cell lines, the majority of
m5U signal present in total RNA from control cell lines
was absent (Figure 1C). The observations suggest that
TRMT2A is the major human m5U methyltransferase.
We next determined the feasibility of 5FU-mediated
crosslinking to identify enzymatic RNA targets of
TRMT2A. We began by performing cellular viability
assays, which showed that a 24 h treatment of a 100 M
5FU concentration inhibited cell proliferation only to
a very limited extent (Supplementary Figure S1), and
these conditions were used for all subsequent experiments.
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The 5FU treatment readily induced crosslinking between
endogenous TRMT2A and RNA (Figure 1D). The yeast
Trm2 m5U methyltransferase contains a key cysteine
residue within its catalytic domain known to be directly
critical for the methyl transfer process (13). In order to
confirm that 5FU-mediated TRMT2A-RNA crosslinking
was dependent on the catalytic activity of TRMT2A, we
used an ectopically expressed TRMT2A construct carrying
a Cys-to-Ala mutation of the corresponding conserved
key catalytic nucleophile residue (catalytic nucleophile
mutant, CNM) (see Supplementary Figure S2); this indeed
resulted in loss of the observed TRMT2A–RNA complex
formation following 5FU exposure (Figure 1E). In parallel
to FICC-Seq, we also performed iCLIP and methylation-
iCLIP experiments; both of these methods were anticipated
to be informative in assessing the robustness of FICC-Seq
to determine enzymatic target sites, as iCLIP detects only
nucleotide-resolution binding sites of a protein whereas
miCLIP further informs on actual methylation target
sites. For iCLIP, UV-exposure was employed to induce
crosslinking between endogenous TRMT2A protein and
RNA (Supplementary Figure S3). FormiCLIP experiments
we referred to alignment of bacterial, yeast and human
m5U methylases (Supplementary Figure S2). The relevant
glutamate residue shown to be required for enzymatic
proton abstraction from the target nucleotide (15) and
thus subsequent resolution of the m5U methylase-RNA
substrate covalent catalytic intermediate (24), was mutated
to alanine in TRMT2A (catalytic base mutant, CBM),
and this point mutant construct was ectopically expressed.
This indeed promoted stabilization of TRMT2A-RNA
crosslinked intermediate complexes (Supplementary Figure
S3), thus indicating TRMT2A miCLIP feasibility.
FICC-Seq demonstrates cytosolic tRNAs to be the major en-
zymatic targets of TRMT2A
TRMT2A FICC-Seq experiments were performed from
both HEK293 and HAP1 cells, and a summary of the
overall methodology is illustrated in Figure 2A and B.
Only around half of the obtained sequence reads mapped
uniquely to the genome (Figure 2C), which was probably
largely due to the presence of a significant proportion of
reads likely mapping to multiple tRNA genes. The major-
ity of uniquely mapping crosslink peaks indeed occurred
on cytosolic tRNA genes (Figure 2D), and this observa-
tion was recapitulated by iCLIP (HEK293 and HAP1) and
miCLIP (HEK293) experiments (Supplementary Table S1).
The small number of crosslink peaks occurring on non-
tRNA genes were further characterized by comparatively
low counts (Figure 2E and Supplementary Table S1); such
minority sites require validation via orthogonal biochemi-
cal methods.
In order to investigate the characteristics of the tRNA
crosslink peaks detected, we initially viewed hits from
FICC-Seq experiments on the UCSC genome browser, and
a few typical examples are shown in Figure 3A (with all
replicates for these available in Supplementary Figure S4).
Along the length of full tRNA genes, we consistently ob-
served a single major peak whilst a smaller associated sub-
peak was also sometimes present (Figure 3A and Supple-
mentary Figure S4). Higher-zoom views of tRNA crosslink
peaks revealed that the major peak predicted precise tar-
geting of U54 of tRNAs, whereas the sub-peak occurred
on position A58 (Figure 3B and Supplementary Figure
S5) which is known to undergo universal modification to
methyl-1-adenosine (m1A). As previously demonstrated,
during cDNA synthesis of tRNAs, reverse transcription
stalling occurs frequently at the nucleotide immediately pre-
ceding tRNA-m1A58 sites (25), which is in accordance with
our observed iCount-annotated peaks occurring precisely
at position A58. However, the major crosslink peaks that
were observed indicate that TRMT2A consistently targets
U54 of cytosolic tRNAs for modification (Figure 3B and
Supplementary Figure S5). Furthermore, a striking enrich-
ment of the universally conserved T-loop motif sequence
of tRNAs was present in the FICC-Seq dataset (Figure
3C), suggesting that enzymatic targeting of tRNA-U54 by
TRMT2A was likely common.
FICC-Seq is a particularly robust method for nucleotide-
resolution detection of TRMT2A enzymatic target sites
To determine the robustness of the FICC-Seq method, we
initially investigated the correlation of genomic crosslink
peak position counts obtained between intra-experimental
biological replicates; better correlations for the FICC-Seq
experiments in comparison to iCLIP and miCLIP exper-
iments were consistently observed (Figure 4). Indeed, al-
though there was good overlap of crosslink peak positions
detected between the different types of experiment (Figure
5A and Supplementary Figure S6), inter-experimental cor-
relation of the crosslink peak position counts was some-
times poor (Figure 5B and Supplementary Figure S7).
Nonetheless, the fact that 93% of the TRMT2A target sites
detected by FICC-Seq were still cross-validated by either
miCLIP and/or iCLIP experiments (Figure 5A) indicates
a low false detection rate of the method.
To investigate the seeming disparity of crosslink peak po-
sitions detected by the different methods further, we com-
piled all of the tRNA crosslink peaks present in each dataset
and plotted them along the length of the full consensus
tRNA sequence (Figure 5C). iCLIP tRNA hits displayed
crosslink peaks in and around the T-loop suggesting that
there may be multiple contact points between TRMT2A
and tRNAs during the methylation process (Figure 5C, top
two panels). Although the likely m1A peak at position 58
was present, methylation-iCLIP demonstrated enzymatic
targeting of position U54 by TRMT2A (Figure 5C, mid-
dle panel); however, minor crosslink peaks across some of
the length of the tRNA, including in the anticodon loop
(A loop), were also observed (Figure 5C, middle panel). As
m5U has never been observed at these additional tRNA
positions in previous studies, these were most likely a re-
sult of off-target detections caused by ectopic expression of
TRMT2A in this particular experiment. In support of the
view that the minor crosslink peaks detected by miCLIP
did not represent true methylation targets of TRMT2A, we
failed to observe these in the FICC-Seq experiments. FICC-
Seq indeed instead displayed a clean detection of targeting
occurring commonly and exclusively at position U54 of tR-
NAs (Figure 5C, bottom two panels).
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Figure 2. The FICC-Seq methodology identifies cytosolic tRNAs as the major enzymatic target of TRMT2A. (A) Summary of FICC-Seq wet-laboratory
methodology. (B) Summary of computational analysis pipeline for sequence reads. (C) Numbers of total Illumina reads obtained from FICC-Seq experi-
ments, along with the numbers of uniquely mapping reads used for downstream analyses. (D) Pie charts showing proportion of FICC-Seq reads mapping to
tRNA (these consisted exclusively of cytosolic tRNAs, Supplementary Table S1) and non-tRNAs (Other). (E) Scatterplot of crosslink peak counts detected
from FICC-Seq-HEK293 versus FICC-Seq-HAP1 experiments.
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Figure 3. FICC-Seq reveals that TRMT2A enzymatically targets U54 within the T-loop of cytosolic tRNAs. (A) FICC-Seq data were viewed as custom
tracks in the UCSC browser with crosslink peaks passing a FDR < 0.05 threshold annotated via our automated UV-iCLIP processing and analysis
pipeline, iCount, and a few typical examples of tRNA hits are shown here. In these low-zoom views, the full tRNA genes are included. The purple bars
represent the relative crosslink site density for the target region included in the view. Along the lengths of tRNAs, just a single major peak was consistently
observed (green arrow), although a common sub-peak was also present (red arrow). (B) Higher-zoom views of a few typical tRNA hits from the TRMT2A
FICC-Seq experiments are shown. As described previously (18,19), the nucleotide immediately following the final nucleotide of UV-iCLIP cDNA reads
usually represent the crosslink site in RNA molecules (due to reverse transcription stalling immediately before the crosslink). In contrast, for catalytic
crosslinking experiments, the crosslinked nucleotide is more often successfully reverse transcribed before resulting in truncation, and in such cases the
nucleotide immediately following the iCount-annotated major crosslink site (i.e. the +1 position) is predicted to be the actual methylated base (6,18),
and these are highlighted in green here. The identified target site in each of these tRNAs corresponds to position U54 in the mature tRNA molecule.
The smaller sub peak was consistently observed to occur 4 nucleotides downstream from the major crosslink site, and this position corresponds to the
universally conserved A58 site in tRNAs. (C) In order to determine whether enrichment of sequences in the immediate vicinity of TRMT2A FICC-Seq
crosslink peaks on tRNA genes were present, a motif search was performed using the motif discovery tool MEME-ChIP. A clear motif consisting of the
universal tRNA T-loop motif GTTCG/AA was detected.
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Figure 4. FICC-Seq presents the most robust crosslink occurrence reproducibility. Intra-experimental comparison of the number of crosslinks counts
detected per peak (FDR< 0.05). Each matrix reports Pearson’s correlation coefficients and corresponding log transformed scatterplots between biological
replicates.
A small number of TRMT2A crosslinks mapping to non-
tRNA genes were detected in our experiments, although
some of these were only detected by iCLIP; a prominent
example is shown in Figure 6. Multiple crosslinks in the 3′
portion of the HIST1H4B transcript were observed from
iCLIP-HEK and iCLIP-HAP experiments. However, these
crosslinks were absent in FICC-Seq and miCLIP experi-
ments (Figure 6), suggesting that TRMT2A stably binds
the HIST1H4B messenger RNA but does not methylate
it. TRMT2A has been demonstrated to be a cell cycle-
regulated protein with peak expression occurring during S-
phase (26–28). Similar to another cell cycle-regulated hu-
manRNAmethyltransferase,NSUN2,which also has enzy-
matic activity-independent functional roles (29), it is quite
likely that TRMT2A has biological roles that are indepen-
dent of it methyltransferase activity; interaction with tran-
scripts such as HIST1H4B messenger RNA might be re-
lated to such additional functional tasks. The potential for
FICC-Seq to distinguish between RNA sites that are enzy-
matically targeted by a modification writer, as opposed to
those that are only bound by it, further underscores the ro-
bustness of the method.
DISCUSSION
In this studywe have developed and usedFICC-Seq to char-
acterize the genome-wide targets of the TRMT2A methyl-
5-uridine writer in human cellular RNA. Our findings re-
veal that TRMT2A is the major human m5U methyltrans-
ferase and that it commonly targets U54 of cytosolic tR-
NAs. Although the primary functions of m5U54 in cy-
tosolic tRNA remain to be determined in detail, it has
recently been shown to be involved in the Toll-like re-
ceptor 7-dependent immune response (30). By establishing
TRMT2A as the human genetic factor likely solely respon-
sible for cytosolic m5U54 formation, our study should aid
further investigations into the regulation of the modifica-
tion and its biological functions.
Although our mass spectrometry experiments demon-
strate that TRMT2A is responsible for the majority of
m5U present in cellular RNA, given the high similar-
ity of the predicted catalytic domain of TRMT2B with
that of its paralogue, it is probable that it too represents
an m5U methyltransferase. A previous study has demon-
strated TRMT2B as a mitochondrial protein (31), and it
has been proposed that it may represent a mitochondrial
tRNA m5U54 methyltransferase (32). Mitochondrial tR-
NAs are non-canonical particularly in terms of their struc-
ture, often for example lacking a T-loop (33), and it has
accordingly been shown that the corresponding cytosolic
m5U54 is in fact sparse in mammalian mitochondrial tR-
NAs (34). Indeed, tRNA m5U54 has thus far only been
shown to be present in two human mitochondrial tRNAs,
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Figure 5. FICC-Seq displays the highest accuracy for TRMT2A enzymatic target-site detection. (A) Venn diagram depicting overlap of genomic crosslink
peak positions (FDR < 0.05) detected by FICC-Seq, miCLIP and iCLIP experiments. Only peaks with a minimum of five crosslink counts are included.
(B)Matrices showing inter-experimental comparison of crosslink peak position counts (FDR< 0.05) via Pearson’s correlation coefficients. Counts for each
experiment were grouped from replicates and normalized as described in the ‘Materials and Methods’ section. (C) For each experiment type, all detected
crosslinks peaks (FDR< 0.05)mapping to tRNAswere compiled in order to gain an overview of targeted positions alongmature tRNAmolecules. Defining
secondary structure regions were identified from tRNAscan-SE results (see ‘Materials andMethods’ section) to form the tRNA structural consensus. tRNA
crosslink site positions were converted relative to the relevant tRNA region they resided in and subsequently plotted on the consensus. For UV-iCLIP
experiments (top two panels), multiple crosslink peaks flanking the U54 position were present, suggesting multiple TRMT2A-tRNA contact points during
the methylation process. For the miCLIP (middle panel) and FICC-Seq (bottom two panels) catalytic crosslinking experiments, a predominant crosslink
peak is present which predicts methylation precisely at position U54 of the tRNA consensus (green arrow). Whilst the expected sub-peak at position A58
corresponding to the m1A modification site (red arrow) can also be observed in FICC-Seq experiments, there is absence of the off-target minor peaks that
are otherwise observed in miCLIP experiments.
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Figure 6. TRMT2A binds to multiple sites in the HIST1H4B messenger RNA but does not target them for enzymatic modification. (A) Crosslinks (FDR
< 0.5) occurring on theHIST1H4B gene from each of the five experiments performed in this study are shown. TheHIST1H4B gene occurs on the negative
DNA strand (hence the negative-oriented peaks), is ∼300 nt in length and contains no introns; the full gene is included in the view. The iCLIP experiments
show that TRMT2A binds to sites in the 3′coding sequence as well as in the 3′UTR. No crosslinks were detected in the miCLIP or FICC-Seq experiments
for this gene. (B) High-zoom view of (A) encompassing only the crosslink sites from the iCLIP experiments.
Leu-UUR (35) and Ser-UCN (36). It is thus possible that
whilst TRMT2A commonly targets cytosolic tRNA-U54,
TRMT2B might instead represent a mitochondrial tRNA
m5U54 methyltransferase with a limited number of actual
targets; appropriate TRMT2B FICC-Seq experiments po-
tentially should be capable of characterizing this further.
It is likely that the FICC-Seq method could also be ap-
plied to profile targets of specific pseudouridine synthases
based on catalytic crosslinking principles (8), given that
the catalytic mechanism of some of these also proceeds via
covalent intermediate formation. For example, similar to
m5Umethyltransferases, some bacterial pseudouridine syn-
thases, such as TruA and RluA, have also been shown to
form stable covalent complexes during the catalytic process
when incubated with tRNA substrates containing 5FU in
place of target uridines (37–39). As the catalytic mecha-
nisms of pseudouridine synthases is thought to be evolu-
tionarily conserved, at the least within phylogenetic fami-
lies, TruA- and RluA-mammalian homologs may also be
amenable to enzyme-specified profiling of the pseudouri-
dine modification via the method.
We have observed significant in vivo TRMT2A-RNA
crosslinking following only reasonable doses of cellular
5FU exposure in our study, which potentially has important
biological implications. For example, it has been shown that
in addition to inhibition of thymidylate synthase, uncharac-
terizedRNA-mediated pathways very likely also play signif-
icant roles in the cytotoxic mechanism of 5FU (40,41). It is
therefore of interest that whilst disruption of pseudouridine
synthase or dihydrouridine synthase, as well as pseudouri-
dine metabolizing enzymes in yeast leads to hypersensitivity
to 5FU, disruption specifically of the TRMT2A homologue
instead leads to some resistance to the compound (42). It is
possible that TRMT2A-RNA crosslinking upon 5FU ex-
posure represents a tangible relevant pathway contributing
to the cytotoxic effect of the drug. A more complete un-
derstanding of such additional cytotoxicity mechanisms of
5FU, an important chemotherapeutic agent, could conceiv-
ably aid in modulating its efficient use.
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